Skip to main content

Brown Ryan Edward's Form 4 filing

Sarepta Therapeutics, Inc.SRPT · filed Jun 25, 2024

Accession no.
0000950170-24-077522
Filed
Jun 25, 2024
Trade date
Jun 21-25, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 10 non-derivative transactions and 4 derivative transactions. Open-market sales total $6.30M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Brown Ryan EdwardCIK 0001848718Officer (EVP, General Counsel)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 21, 2024Common StockMOption exerciseAcquired+6,250–F1–34,938Direct
Jun 24, 2024Common StockFTax withholdingDisposed−2,352$164.64−$387,233.2832,586Direct
Jun 25, 2024Common StockMOption exerciseAcquired+23,500$62.77+$1,475,09556,086Direct
Jun 25, 2024Common StockSSaleDisposed−7,644$158.07F4−$1,208,287.0848,442Direct
Jun 25, 2024Common StockSSaleDisposed−2,200$159.14F5−$350,10846,242Direct
Jun 25, 2024Common StockSSaleDisposed−975$160.31F6−$156,302.2545,267Direct
Jun 25, 2024Common StockSSaleDisposed−4,168$161.82F7−$674,465.7641,099Direct
Jun 25, 2024Common StockSSaleDisposed−17,581$162.65F8−$2,859,549.6523,518Direct
Jun 25, 2024Common StockSSaleDisposed−3,840$163.53F9−$627,955.219,678Direct
Jun 25, 2024Common StockSSaleDisposed−2,549$164.52−$419,361.4817,129Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 21, 2024Common StockAGrant or awardAcquired+5,500$0.00$05,500Direct
Jun 21, 2024Common StockAGrant or awardAcquired+6,250$0.00$06,250Direct
Jun 21, 2024Common StockMOption exerciseDisposed−6,250$0.00$00Direct
Jun 25, 2024Common StockMOption exerciseDisposed−23,500$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.58 to $158.52, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.67 to $159.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.71 to $160.69, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.04 to $162.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.12 to $163.09, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.19 to $163.98 inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)